Literature DB >> 8660296

High-density lipoprotein 3 physicochemical modifications induced by interaction with human polymorphonuclear leucocytes affect their ability to remove cholesterol from cells.

A Cogny1, V Atger, J L Paul, T Soni, N Moatti.   

Abstract

1. We have recently reported that a short incubation (60 min) in vitro of high-density lipoprotein (HDL) 3 with human polymorphonuclear leucocytes (PMNs) leads to a proteolytic cleavage of apolipoprotein (apo) AII and to a change in the distribution of apo AI isoforms [Cogny, Paul, Atger, Soni and Moatti (1994) Eur. J. Biochem. 222, 965-973]. Since PMNs have been observed to be present in the earliest atherosclerotic lesions for a number of days, we investigated the HDL3 physiochemical modifications induced by in vitro interaction for a long period of time (24 h) with PMNs and the consequences of the changes on the ability of HDL3 to remove cholesterol from cells. 2. The stimulated PMN modification of HDL3 over 24 h resulted in a partial loss of protein with no variation in lipid molar ratio and a loss of 50% of HDL alpha-tocopherol content. The decrease in total protein was due first to a complete degradation of apo AII, and secondly to a partial loss of apo AI. The apo AI remaining on the particles was in part hydrolysed and the apo AI-1 isoform was completely shifted to the apo AI-2 isoform. These apo changes were accompanied by a displacement of the native HDL3 apparent size toward predominantly larger particles. 3. The ability of PMN-modified HDL3 to remove 3H-labelled free cholesterol from cells was measured in two cell lines: Fu5AH rat hepatoma cells and J774 mouse macrophages. HDL3 which had only a limited contact with PMNs (60 min) showed only a small non-significant reduction in the efficiency of cholesterol efflux. On the other hand, compared with native HDL3, HDL3 modified by PMNs for 24 h had a markedly reduced ability to remove cholesterol from cells, regardless of the type of cell. 4. The results suggest that PMN-modified HDL3, if occurring in vivo, could contribute to acceleration of the atherogenic process by decreasing the cholesterol efflux from cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660296      PMCID: PMC1217038          DOI: 10.1042/bj3140285

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  50 in total

Review 1.  Tracking cell cholesterol with cholesterol oxidase.

Authors:  Y Lange
Journal:  J Lipid Res       Date:  1992-03       Impact factor: 5.922

Review 2.  Mechanisms of endothelial cell injury.

Authors:  P A Ward
Journal:  J Lab Clin Med       Date:  1991-11

3.  High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification.

Authors:  Y Nagano; H Arai; T Kita
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

4.  Malondialdehyde modification and copper-induced autooxidation of high-density lipoprotein decrease cholesterol efflux from human cultured fibroblasts.

Authors:  S Salmon; C Mazière; M Auclair; L Theron; R Santus; J C Mazière
Journal:  Biochim Biophys Acta       Date:  1992-04-23

5.  Cholesterol efflux from macrophages mediated by high-density lipoprotein subfractions, which differ principally in apolipoprotein A-I and apolipoprotein A-II ratios.

Authors:  E von Hodenberg; S Heinen; K E Howell; C Luley; W Kübler; H M Bond
Journal:  Biochim Biophys Acta       Date:  1991-11-05

6.  Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III.

Authors:  A von Eckardstein; M Walter; H Holz; A Benninghoven; G Assmann
Journal:  J Lipid Res       Date:  1991-09       Impact factor: 5.922

Review 7.  Cholesterol transport between cells and high-density lipoproteins.

Authors:  W J Johnson; F H Mahlberg; G H Rothblat; M C Phillips
Journal:  Biochim Biophys Acta       Date:  1991-10-01

8.  The bidirectional flux of cholesterol between cells and lipoproteins. Effects of phospholipid depletion of high density lipoprotein.

Authors:  W J Johnson; M J Bamberger; R A Latta; P E Rapp; M C Phillips; G H Rothblat
Journal:  J Biol Chem       Date:  1986-05-05       Impact factor: 5.157

Review 9.  Role of granulocytes in endothelial injury in coronary heart disease in humans.

Authors:  G Ricevuti; A Mazzone; D Pasotti; S de Servi; G Specchia
Journal:  Atherosclerosis       Date:  1991-11       Impact factor: 5.162

10.  Ascorbic acid in human neutrophils.

Authors:  P Washko; D Rotrosen; M Levine
Journal:  Am J Clin Nutr       Date:  1991-12       Impact factor: 7.045

View more
  5 in total

Review 1.  High-density lipoprotein: is it always atheroprotective?

Authors:  Benjamin J Ansell; Gregg C Fonarow; Alan M Fogelman
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

Review 2.  Oxidative risk for atherothrombotic cardiovascular disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Free Radic Biol Med       Date:  2009-09-12       Impact factor: 7.376

Review 3.  Dysfunctional HDL as a diagnostic and therapeutic target.

Authors:  Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-13       Impact factor: 8.311

4.  Neutrophils to high-density lipoprotein cholesterol ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a retrospective study.

Authors:  Yun Chen; Dan Jiang; Hongmei Tao; Ping Ge; Qin Duan
Journal:  BMC Cardiovasc Disord       Date:  2022-10-05       Impact factor: 2.174

Review 5.  Non-clinical development of CER-001.

Authors:  Ronald Barbaras
Journal:  Front Pharmacol       Date:  2015-10-06       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.